Theorem Clinical Research

Drug Sponsors

BioFusionary to complete reverse takeover of Continuation Investments

Wednesday, July 30, 2014 12:30 PM

Colorado-based BioFusionary, a medical technology company focused on developing a proprietary electromagnetic induction platform with aesthetic and surgical applications, has entered into an agreement under which BioFusionary will merge with Australia-based Continuation Investments in an all-stock transaction.

More... »


Amgen to cut up to 3,000 jobs, most in U.S., close facilities

Wednesday, July 30, 2014 11:42 AM

Amgen has announced a restructuring plan to invest in continuing innovation and the launch of its new pipeline molecules, while improving cost structure.

More... »


ABPI establishes Inward Investor Group

Wednesday, July 23, 2014 10:45 AM

The Association of the British Pharmaceutical Industry (ABPI) has established a new Inward Investor Group to demonstrate the importance of inward investment to the U.K. and the global mobility of such investment. The group also will work toward cultivating a favorable environment for pharmaceutical companies to invest in the U.K.

More... »

Cipla to expand global footprint, investing in U.K. subsidiary

Wednesday, July 23, 2014 10:42 AM

India-based Cipla has announced a collaboration with the U.K. government to invest up to $170 million in its U.K. subsidiary over the next few years.

More... »

Allergan to restructure, cutting 1,500 employees

Monday, July 21, 2014 03:35 PM

As a result of a review of its operations and processes, Allergan will execute a restructuring it estimates will deliver annual pre-tax savings of approximately $475 million in calendar year 2015. Allergan will focus resources on the highest value opportunities, streamline its organizational structure, simplify processes and interfaces, optimize site footprints and enhancie strategic sourcing of goods and services.

More... »

AstraZeneca reveals designs for new U.K. global R&D center, corporate headquarters

Monday, July 21, 2014 03:03 PM

AstraZeneca revealed its proposed designs for its new global R&D center and corporate headquarters in Cambridge, U.K. The facility, which will be located on the Cambridge Biomedical Campus (CBC), includes the global center, an R&D enabling building and an energy center.

More... »

AbbVie to acquire Shire in $54.6 billion deal

Friday, July 18, 2014 10:24 AM

The boards of AbbVie and Shire have reached agreement on the terms of a recommended combination of Shire with AbbVie that values Shire at approximately $54.61 billion.

More... »

Pfizer to acquire InnoPharma

Thursday, July 17, 2014 12:48 PM

Pfizer has entered an agreement to acquire InnoPharma, a privately held pharmaceutical development company, for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.

More... »

Shire willing to discuss AbbVie’s 5th revised proposal

Monday, July 14, 2014 12:48 PM

Following discussions with AbbVie, Shirerequested and has received a further revised proposal from AbbVie on July 13 for a total offering of $53 billion.

More... »

Abbott to sell generics pharmaceuticals business to Mylan, form new entity

Monday, July 14, 2014 12:47 PM

Abbott will sell its non-U.S. developed markets branded generics pharmaceuticals business to Mylan for 105 million shares, or approximately 21%, on a fully diluted basis, of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business. The new entity will be a publicly traded company. This represents a value of approximately $5.3 billion based on Mylan's closing stock price on Friday.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 13

First Sunshine Act data posted online; many cite errors, lack of context to help consumers understand payments

In appreciation: Felix Gyi will be remembered for his passion, leadership and desire to educate, pay it forward

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs